ClinicalTrials.gg
CompletedNCT04053023Updated Jul 24, 2020Results posted

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects

A Phase 1 interventional study of GSK2330672 (linerixibat) and Obeticholic acid in Cholestasis, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-24.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Cholestasis with a site in United Kingdom — 1 open to participants now, 3 under way, 1 of them phase 3. Cholestasis · United Kingdom.

Enrollment
13th of 15
19 · median 62
Started
2019
with 2 others
Phase 1
2 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
5 of 17
GlaxoSmithKline

Among the 17 studies in Cholestasis with a site in United Kingdom, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 10th registered.

Cholestasis

150 studies on the registry are indexed under Cholestasis; 18 are open to participants now.

Browse Cholestasis studies →

Open to participants now

1 of the 17 studies in Cholestasis with a site in United Kingdom is open now. Recruiting first, the newest first:

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 9 Cholestasis studies recruiting now, 1 sets no upper age limit and 8 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Cholestasis with a site in United Kingdom, or all of them as a file.
02

Study summary

In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA therapy may be considered following marketing approval. It is therefore important to characterize any potential effect of linerixibat on the pharmacokinetics of OCA in humans at clinically relevant dosages. Accordingly, a drug-drug interaction (DDI) study with linerixibat (potential perpetrator) and OCA (potential victim) will be conducted to inform both future clinical trials with linerixibat and the potential concomitant administration of these drugs in a clinical setting. This is a single-center, one part (with optional second part) open-label, single sequence crossover, drug interaction study to investigate the effect of linerixibat on plasma concentrations of OCA and OCA conjugates in healthy participants. Approximately 19 participants will be enrolled in part A and further 19 participants in part B (if performed) in the study and will have a phone call follow-up till 7-14 days post-last linerixibat dose.

03

Conditions studied

  • Cholestasis

Keywords

  • linerixibat (GSK2330672), obeticholic acid, drug interaction, primary biliary cholangitis, pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 80 years of age inclusive, at the time of signing the .
  • Healthy, as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and . A participant with a clinical abnormality or laboratory parameter (i.e., outside the reference range for the population being studied), which is not specifically listed in the eligibility criteria, may be included only if the investigator agrees in consultation with the GlaxoSmithKline (GSK) medical monitor and documents in the source documentation that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures or outcomes.
  • Body weight > 50 kilogram (kg) and (BMI) within the range 18.5 to 32 kg per square meter (inclusive).
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.
  • Male and female- A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies; not a woman of (WOCBP) or a WOCBP who agrees to follow guidance during the treatment period and until at least 4 weeks after the last dose of study treatment. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Any active dermatologic disorder leading to or with the potential to cause pruritus or a recent history of unexplained itching locally or generally within the prior 3 months
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) and/or confirmed hepatocellular carcinoma or biliary cancer
  • Participants with a history of cholecystectomy
  • Current symptomatic cholelithiasis or inflammatory gall bladder disease
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
  • Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history) clinical laboratory tests, or 12-lead
  • Current episode, recent history (within 1 month of screening visit), or chronic history of clinically significant diarrhea
  • Lymphoma, leukaemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Any current medical condition (e.g. psychiatric disorder, senility, dementia, or other condition), clinical or laboratory abnormality, or examination finding that the investigator considers would put the participant at unacceptable risk, which may affect study compliance or prevent understanding of the aims or procedures or possible consequences of the study
  • Regular use of known drugs of abuse or history of drug abuse or dependence within 6 months of the study
  • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >14 units for females and >21 units for males. One unit is equivalent to 8 gram of alcohol: a glass (approximately [\~] 240 milliliter [mL]) of beer, 1 small glass (\~100 mL) of wine or 1 (\~25 mL) measure of spirits
  • History of or regular use of tobacco- or nicotine-containing products (confirmed by smokerlyzer test) in the 3 months prior to screening.
  • Administration of any IBAT inhibitor (including linerixibat) or OCA in the 3 months prior to screening
  • Past or intended use of over-the-counter or prescription medication (including vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inhibitor) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless approved by the investigator in conjunction with GSK medical monitor.
  • Current enrollment in a clinical trial, recent participation in a clinical trial and has received an investigational product within 30 days (or 5 half-lives of previous trial intervention, whichever is longer) before the first dose in the current study
  • Exposure to more than 4 new chemical entities within 12 months before the first dose in the current study.
  • Screening or AST >1.5 times the (ULN)
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • Presence of surface antigen (HBsAg) at screening or positive antibody test result at screening or within 3 months of the screening visit
  • Positive serum pregnancy test at screening or positive urine pregnancy test at admission in only
  • Positive (HIV) antibody test
  • >450 millisecond (msec) on ECG performed at screening.
  • Positive pre-study drug/alcohol screen or positive drug/alcohol screen at any time during the study.
  • Female participants unable or unwilling to comply with specific restrictions.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56-day period.
  • Unwillingness or inability to follow the procedures outlined in the protocol for the expected duration of study participation.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Participants receiving obeticholic acid and linerixibat

    In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.

    Drug: GSK2330672 (linerixibat) · Drug: Obeticholic acid

Interventions

  • GSK2330672 is available as a tablet with unit dose strength of 45 mg.

  • Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).

06

What researchers measure

Primary outcomes

  1. Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  2. Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  3. Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  4. Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  5. Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  6. Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  7. Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  8. Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  9. Part B- AUC(0-t) for Total-OCA at Steady State: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  10. Part B- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  11. Part B- AUC(0-24) for Total-OCA at Steady State: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  12. Part B- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  13. Part B- Cmax for Total-OCA at Steady State: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  14. Part B- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  15. Part B- Ctrough for Total-OCA at Steady State: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  16. Part B- Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

Secondary outcomes

  1. Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  2. Part A- Tmax for Total-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  3. Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 19) post-dose

  4. Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 38) post-dose

  5. Part A- AUC(0-t) for OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  6. Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  7. Part A- AUC(0-24) for OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  8. Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  9. Part A- Cmax for OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  10. Part A- Cmax for OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  11. Part A- Average Ctrough for OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  12. Part A- Average Ctrough for OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  13. Part A- Tmax for OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  14. Part A- Tmax for OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  15. Part A- AUC(0-t) for Tauro-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  16. Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  17. Part A- AUC(0-24) for Tauro-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  18. Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  19. Part A- Cmax for Tauro-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  20. Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  21. Part A- Average Ctrough for Tauro-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  22. Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  23. Part A- Tmax for Tauro-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  24. Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  25. Part A- AUC(0-t) for Glyco-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  26. Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  27. Part A- AUC(0-24) for Glyco-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  28. Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  29. Part A- Cmax for Glyco-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  30. Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  31. Part A- Average Ctrough for Glyco-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  32. Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  33. Part A- Tmax for Glyco-OCA: OCA Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  34. Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  35. Part B- Tmax for Total-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  36. Part B- Tmax for Total-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  37. Part B- AUC(0-t) for OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  38. Part B- AUC(0-t) for OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  39. Part B- AUC(0-24) for OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  40. Part B- AUC(0-24) for OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  41. Part B- Cmax for OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  42. Part B- Cmax for OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  43. Part B- Ctrough for OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  44. Part B- Ctrough for OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  45. Part B- Tmax for OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  46. Part B- Tmax for OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  47. Part B- AUC(0-t) for Tauro-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  48. Part B- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  49. Part B- AUC(0-24) for Tauro-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  50. Part B- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  51. Part B- Cmax for Tauro-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  52. Part B- Cmax for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  53. Part B- Ctrough for Tauro-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  54. Part B- Ctrough for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  55. Part B- Tmax for Tauro-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  56. Part B- Tmax for Tauro-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  57. Part B- AUC(0-t) for Glyco-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  58. Part B- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  59. Part B- AUC(0-24) for Glyco-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  60. Part B- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  61. Part B- Cmax for Glyco-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  62. Part B- Cmax for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  63. Part B- Ctrough for Glyco-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  64. Part B- Ctrough for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  65. Part B- Tmax for Glyco-OCA: OCA Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

  66. Part B- Tmax for Glyco-OCA: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

    Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

  67. Part A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.

    Time frame: Up to Day 52

  68. Part B- Number of Participants With Any AEs and SAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.

    Time frame: Up to Day 52

  69. Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm

    Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1), and at Day 17

  70. Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm

    Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1), and at Day 38

  71. Part B- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF

    Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.

    Time frame: Baseline (Day -1), and up to Day 38

  72. Part A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm

    SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1), Days 1 and 17

  73. Part A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm

    SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  74. Part A- Change From Baseline in Pulse Rate: OCA Arm

    Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1), Days 1 and 17

  75. Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm

    Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  76. Part A- Change From Baseline in Respiratory Rate: OCA Arm

    Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1), Days 1 and 17

  77. Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm

    Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  78. Part A- Change From Baseline in Body Temperature: OCA Arm

    Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1), Days 1 and 17

  79. Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm

    Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  80. Part B- Change From Baseline in SBP and DBP

    SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

    Time frame: Baseline (Day -1), and up to Day 38

  81. Part B- Change From Baseline in Pulse Rate

    Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

    Time frame: Baseline (Day -1), and up to Day 38

  82. Part B- Change From Baseline in Respiratory Rate

    Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

    Time frame: Baseline (Day -1), and up to Day 38

  83. Part B- Change From Baseline in Body Temperature

    Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

    Time frame: Baseline (Day -1), and up to Day 38

  84. Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm

    Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  85. Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm

    Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  86. Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  87. Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  88. Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  89. Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  90. Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  91. Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  92. Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  93. Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  94. Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm

    Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  95. Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm

    Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  96. Part B- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes

    Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.

    Time frame: Baseline (Day -1), and up to Day 38

  97. Part B- Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.

    Time frame: Baseline (Day -1), and up to Day 38

  98. Part B- Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.

    Time frame: Baseline (Day -1), and up to Day 38

  99. Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

    Time frame: Baseline (Day -1), and up to Day 38

  100. Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

    Time frame: Baseline (Day -1), and up to Day 38

  101. Part B- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes

    Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.

    Time frame: Baseline (Day -1), and up to Day 38

  102. Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm

    Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  103. Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm

    Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  104. Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm

    Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  105. Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm

    Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  106. Part A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm

    Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  107. Part A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm

    Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  108. Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm

    Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 17

  109. Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm

    Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and at Day 38

  110. Part B- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea

    Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.

    Time frame: Baseline (Day -1), and up to Day 38

  111. Part B- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin

    Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.

    Time frame: Baseline (Day -1), and up to Day 38

  112. Part B- Change From Baseline in Chemistry Parameters: ALT, ALP, AST

    Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.

    Time frame: Baseline (Day -1), and up to Day 38

  113. Part B- Change From Baseline in Chemistry Parameter: Protein

    Blood samples were planned to be collected to analyze the chemistry parameter: protein.

    Time frame: Baseline (Day -1), and up to Day 38

  114. Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm

    Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.

    Time frame: Baseline (Day -1) and at Day 17

  115. Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm

    Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.

    Time frame: Baseline (Day -1) and at Day 38

  116. Part B- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.

    Time frame: Baseline (Day -1), and up to Day 38

  117. Part A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  118. Part A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  119. Part A- Cmax for Linerixibat: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  120. Part A- Tmax for Linerixibat: OCA + Linerixibat Arm

    Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  121. Part B- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  122. Part B- AUC(0-12) for Linerixibat: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  123. Part B- Cmax for Linerixibat: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

  124. Part B- Tmax for Linerixibat: OCA + Linerixibat Arm

    Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

    Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

07

Results

Posted Jul 24, 2020

Participant flow

This was an open-label, drug interaction study to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and OCA conjugates in healthy participants. The study was conducted at a single center in the United Kingdom.

Part A: Period 1 (Day 1 to Day 19)
Participant flow — Part A: Period 1 (Day 1 to Day 19)
MilestonePart A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg
Started190
Completed190
Not completed00
Part A: Period 2 (Day 20 to Day 38)
Participant flow — Part A: Period 2 (Day 20 to Day 38)
MilestonePart A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg
Started190
Completed180
Not completed10
Withdrew: Adverse event10
Part B: Period 1 (Day 1 to Day 19)
Participant flow — Part B: Period 1 (Day 1 to Day 19)
MilestonePart A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg
Started00
Completed00
Not completed00
Part B: Period 2 (Day 20 to Day 38)
Participant flow — Part B: Period 2 (Day 20 to Day 38)
MilestonePart A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg
Started00
Completed00
Not completed00

Outcome measures

PrimaryPart A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm2329.804 ± 43.54
PrimaryPart A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm782.528 ± 55.81
PrimaryPart A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm2349.552 ± 43.55
PrimaryPart A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm787.007 ± 55.17
PrimaryPart A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm206.409 ± 41.18
PrimaryPart A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm83.403 ± 45.55
PrimaryPart A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm85.312 ± 53.13
PrimaryPart A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm21.680 ± 85.11
PrimaryPart B- AUC(0-t) for Total-OCA at Steady State: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

PrimaryPart B- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

PrimaryPart B- AUC(0-24) for Total-OCA at Steady State: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

PrimaryPart B- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

PrimaryPart B- Cmax for Total-OCA at Steady State: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

PrimaryPart B- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

PrimaryPart B- Ctrough for Total-OCA at Steady State: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

PrimaryPart B- Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Median · Hours
Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm
HoursPart A: OCA 10 mg
Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm1.00 (0.3 to 5.0)
SecondaryPart A- Tmax for Total-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Median · Hours
Part A- Tmax for Total-OCA: OCA + Linerixibat Arm
HoursPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Tmax for Total-OCA: OCA + Linerixibat Arm3.00 (0.5 to 6.0)
SecondaryPart A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 19) post-dose
Reported as:
Mean · Nanogram per milliliter
Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Day 1792.1116 ± 57.86113
Day 1895.1600 ± 57.50955
Day 19102.5168 ± 66.65649
SecondaryPart A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 38) post-dose
Reported as:
Mean · Nanogram per milliliter
Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Day 3530.8972 ± 25.55139
Day 3628.8489 ± 27.08479
Day 3726.4411 ± 21.63264
Day 3827.8644 ± 21.08848
SecondaryPart A- AUC(0-t) for OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for OCA: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- AUC(0-t) for OCA: OCA Arm158.337 ± 59.45
SecondaryPart A- AUC(0-t) for OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm127.171 ± 53.12
SecondaryPart A- AUC(0-24) for OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-24) for OCA: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- AUC(0-24) for OCA: OCA Arm163.701 ± 59.51
SecondaryPart A- AUC(0-24) for OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours * nanogram per milliliter
Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm
Hours * nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm130.092 ± 53.80
SecondaryPart A- Cmax for OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Cmax for OCA: OCA Arm50.820 ± 71.94
SecondaryPart A- Cmax for OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Cmax for OCA: OCA + Linerixibat Arm35.495 ± 61.88
SecondaryPart A- Average Ctrough for OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Average Ctrough for OCA: OCA Arm2.609 ± 69.77
SecondaryPart A- Average Ctrough for OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Average Ctrough for OCA: OCA + Linerixibat Arm2.060 ± 83.57
SecondaryPart A- Tmax for OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Median · Hours
Part A- Tmax for OCA: OCA Arm
HoursPart A: OCA 10 mg
Part A- Tmax for OCA: OCA Arm0.75 (0.3 to 11.0)
SecondaryPart A- Tmax for OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Median · Hours
Part A- Tmax for OCA: OCA + Linerixibat Arm
HoursPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Tmax for OCA: OCA + Linerixibat Arm0.88 (0.5 to 12.0)
SecondaryPart A- AUC(0-t) for Tauro-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for Tauro-OCA: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- AUC(0-t) for Tauro-OCA: OCA Arm712.567 ± 61.28
SecondaryPart A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm89.486 ± 64.85
SecondaryPart A- AUC(0-24) for Tauro-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-24) for Tauro-OCA: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- AUC(0-24) for Tauro-OCA: OCA Arm744.365 ± 68.92
SecondaryPart A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm89.946 ± 64.50
SecondaryPart A- Cmax for Tauro-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for Tauro-OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Cmax for Tauro-OCA: OCA Arm62.347 ± 60.84
SecondaryPart A- Cmax for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm10.224 ± 61.53
SecondaryPart A- Average Ctrough for Tauro-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for Tauro-OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Average Ctrough for Tauro-OCA: OCA Arm28.014 ± 76.45
SecondaryPart A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm2.600 ± 124.06
SecondaryPart A- Tmax for Tauro-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Median · Hours
Part A- Tmax for Tauro-OCA: OCA Arm
HoursPart A: OCA 10 mg
Part A- Tmax for Tauro-OCA: OCA Arm2.00 (0.3 to 11.0)
SecondaryPart A- Tmax for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Median · Hours
Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm
HoursPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm5.00 (2.0 to 9.0)
SecondaryPart A- AUC(0-t) for Glyco-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for Glyco-OCA: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- AUC(0-t) for Glyco-OCA: OCA Arm1741.969 ± 44.11
SecondaryPart A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm650.683 ± 58.17
SecondaryPart A- AUC(0-24) for Glyco-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-24) for Glyco-OCA: OCA Arm
Hours*nanogram per milliliterPart A: OCA 10 mg
Part A- AUC(0-24) for Glyco-OCA: OCA Arm1757.140 ± 44.10
SecondaryPart A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm
Hours*nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm654.629 ± 57.45
SecondaryPart A- Cmax for Glyco-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for Glyco-OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Cmax for Glyco-OCA: OCA Arm141.770 ± 39.46
SecondaryPart A- Cmax for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm65.633 ± 50.27
SecondaryPart A- Average Ctrough for Glyco-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for Glyco-OCA: OCA Arm
Nanogram per milliliterPart A: OCA 10 mg
Part A- Average Ctrough for Glyco-OCA: OCA Arm66.043 ± 50.72
SecondaryPart A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm
Nanogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm19.498 ± 85.88
SecondaryPart A- Tmax for Glyco-OCA: OCA Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Reported as:
Median · Hours
Part A- Tmax for Glyco-OCA: OCA Arm
HoursPart A: OCA 10 mg
Part A- Tmax for Glyco-OCA: OCA Arm2.00 (0.3 to 5.0)
SecondaryPart A- Tmax for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Reported as:
Median · Hours
Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm
HoursPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm5.00 (1.0 to 6.0)
SecondaryPart B- Tmax for Total-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for Total-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-t) for OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-t) for OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-24) for OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-24) for OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Ctrough for OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Ctrough for OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-t) for Tauro-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-24) for Tauro-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for Tauro-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Ctrough for Tauro-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Ctrough for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for Tauro-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for Tauro-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-t) for Glyco-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-24) for Glyco-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for Glyco-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Ctrough for Glyco-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Ctrough for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for Glyco-OCA: OCA Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for Glyco-OCA: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.

Time frame:
Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose

No measurements were reported for this outcome.

SecondaryPart A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.

Time frame:
Up to Day 52
Reported as:
Count of participants · Participants
Part A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: OCA 10 mgPart A: OCA 10 mg + Linerixibat 90 mg
Any AEs1014
Any SAEs01
SecondaryPart B- Number of Participants With Any AEs and SAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.

Time frame:
Up to Day 52

No measurements were reported for this outcome.

SecondaryPart A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm

Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1), and at Day 17
Reported as:
Mean · Millisecond
Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm
MillisecondPart A: OCA 10 mg
PR Interval-3.7 ± 8.27
QRS Duration-1.2 ± 4.66
QT Interval-3.4 ± 14.56
QTcB Interval4.2 ± 13.31
QTcF Interval1.6 ± 10.43
SecondaryPart A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm

Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1), and at Day 38
Reported as:
Mean · Millisecond
Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm
MillisecondPart A: OCA 10 mg + Linerixibat 90 mg
PR Interval2.5 ± 12.96
QRS Duration-2.3 ± 2.97
QT Interval-2.7 ± 13.05
QTcB Interval-2.9 ± 13.18
QTcF Interval-2.9 ± 9.58
SecondaryPart B- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF

Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm

SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1), Days 1 and 17
Reported as:
Mean · Millimeters of mercury
Part A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm
Millimeters of mercuryPart A: OCA 10 mg
SBP: Day 1-0.9 ± 6.83
SBP: Day 170.5 ± 5.94
DBP: Day 1-4.5 ± 4.17
DBP: Day 170.1 ± 3.96
SecondaryPart A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm

SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Millimeters of mercury
Part A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm
Millimeters of mercuryPart A: OCA 10 mg + Linerixibat 90 mg
SBP-0.7 ± 8.48
DBP0.8 ± 2.98
SecondaryPart A- Change From Baseline in Pulse Rate: OCA Arm

Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1), Days 1 and 17
Reported as:
Mean · Beats per minute
Part A- Change From Baseline in Pulse Rate: OCA Arm
Beats per minutePart A: OCA 10 mg
Day 17.2 ± 6.54
Day 171.8 ± 7.45
SecondaryPart A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm

Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Beats per minute
Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm
Beats per minutePart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm-0.3 ± 8.96
SecondaryPart A- Change From Baseline in Respiratory Rate: OCA Arm

Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1), Days 1 and 17
Reported as:
Mean · Breaths per minute
Part A- Change From Baseline in Respiratory Rate: OCA Arm
Breaths per minutePart A: OCA 10 mg
Day 10.2 ± 1.95
Day 170.4 ± 1.77
SecondaryPart A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm

Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Breaths per minute
Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm
Breaths per minutePart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm0.4 ± 2.09
SecondaryPart A- Change From Baseline in Body Temperature: OCA Arm

Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1), Days 1 and 17
Reported as:
Mean · Degrees Celsius
Part A- Change From Baseline in Body Temperature: OCA Arm
Degrees CelsiusPart A: OCA 10 mg
Day 10.15 ± 0.356
Day 170.05 ± 0.336
SecondaryPart A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm

Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Degrees Celsius
Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm
Degrees CelsiusPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm0.09 ± 0.327
SecondaryPart B- Change From Baseline in SBP and DBP

SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Pulse Rate

Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Respiratory Rate

Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Body Temperature

Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · 10^9 cells per liter
Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm
10^9 cells per literPart A: OCA 10 mg
Basophils-0.002 ± 0.0144
Eosinophils-0.013 ± 0.0549
Lymphocytes-0.091 ± 0.4444
Monocytes0.033 ± 0.1125
Neutrophils0.064 ± 0.8205
Platelet count4.3 ± 22.85
Leukocytes-0.011 ± 0.7760
SecondaryPart A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · 10^9 cells per liter
Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm
10^9 cells per literPart A: OCA 10 mg + Linerixibat 90 mg
Basophils0.000 ± 0.0091
Eosinophils0.029 ± 0.0801
Lymphocytes0.169 ± 0.3534
Monocytes0.047 ± 0.0932
Neutrophils0.278 ± 1.2073
Platelet count-4.1 ± 20.77
Leukocytes0.524 ± 1.1981
SecondaryPart A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Grams per liter
Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm
Grams per literPart A: OCA 10 mg
Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm0.4 ± 6.33
SecondaryPart A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Grams per liter
Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm
Grams per literPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm-0.8 ± 5.09
SecondaryPart A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Proportion of red blood cells in blood
Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm
Proportion of red blood cells in bloodPart A: OCA 10 mg
Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm-0.0003 ± 0.01614
SecondaryPart A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Proportion of red blood cells in blood
Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm
Proportion of red blood cells in bloodPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm-0.0054 ± 0.01857
SecondaryPart A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Picograms
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm
PicogramsPart A: OCA 10 mg
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm-0.01 ± 0.624
SecondaryPart A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Picograms
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm
PicogramsPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm-0.13 ± 0.552
SecondaryPart A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Femtoliter
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm
FemtoliterPart A: OCA 10 mg
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm-0.37 ± 1.797
SecondaryPart A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Femtoliter
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm
FemtoliterPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm-1.03 ± 1.972
SecondaryPart A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm

Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · 10^12 cells per liter
Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm
10^12 cells per literPart A: OCA 10 mg
Erythrocytes0.021 ± 0.1919
Reticulocytes-0.0004 ± 0.01165
SecondaryPart A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm

Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · 10^12 cells per liter
Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm
10^12 cells per literPart A: OCA 10 mg + Linerixibat 90 mg
Erythrocytes0.002 ± 0.2340
Reticulocytes0.0074 ± 0.01650
SecondaryPart B- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes

Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes

Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm

Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Millimoles per liter
Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm
Millimoles per literPart A: OCA 10 mg
Glucose-0.09 ± 0.537
Calcium0.041 ± 0.0891
Potassium-0.02 ± 0.429
Sodium-0.2 ± 2.10
Urea-0.0395 ± 0.32717
SecondaryPart A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm

Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Millimoles per liter
Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm
Millimoles per literPart A: OCA 10 mg + Linerixibat 90 mg
Glucose, n=18-0.44 ± 0.343
Calcium, n=18-0.001 ± 0.0506
Potassium, n=160.10 ± 0.493
Sodium, n=18-0.9 ± 1.89
Urea, n=18-0.1507 ± 0.24902
SecondaryPart A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm

Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Micromoles per liter
Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm
Micromoles per literPart A: OCA 10 mg
Bilirubin0.1 ± 2.42
Creatinine-2.2 ± 7.71
Direct Bilirubin0.0001 ± 0.88192
SecondaryPart A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm

Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Micromoles per liter
Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm
Micromoles per literPart A: OCA 10 mg + Linerixibat 90 mg
Bilirubin, n=181.1 ± 2.72
Creatinine, n=185.4 ± 6.83
Direct Bilirubin, n=160.3126 ± 0.79317
SecondaryPart A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm

Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · International units per liter
Part A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm
International units per literPart A: OCA 10 mg
ALT-2.7 ± 4.75
ALP0.6 ± 5.50
AST-2.2 ± 3.03
SecondaryPart A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm

Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · International units per liter
Part A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm
International units per literPart A: OCA 10 mg + Linerixibat 90 mg
ALT, n=179.4 ± 38.04
ALP, n=180.0 ± 9.49
AST, n=16-0.9 ± 8.50
SecondaryPart A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm

Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Mean · Grams per liter
Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm
Grams per literPart A: OCA 10 mg
Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm1.5 ± 3.13
SecondaryPart A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm

Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Mean · Grams per liter
Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm
Grams per literPart A: OCA 10 mg + Linerixibat 90 mg
Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm0.7 ± 2.66
SecondaryPart B- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea

Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin

Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Chemistry Parameters: ALT, ALP, AST

Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart B- Change From Baseline in Chemistry Parameter: Protein

Blood samples were planned to be collected to analyze the chemistry parameter: protein.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm

Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.

Time frame:
Baseline (Day -1) and at Day 17
Reported as:
Count of participants · Participants
Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm
ParticipantsPart A: OCA 10 mg
Cellular casts: No change5
Cellular casts: Increase to 1-9/HPF0
Erythrocytes: No change4
Erythrocytes: Increase to 1-9/HPF1
Granular casts: No change5
Granular casts: Increase to 1-9/HPF0
Hyaline casts: No change5
Hyaline casts: Increase to 1-9/HPF0
Leukocytes: No change4
Leukocytes: Increase to 1-9/HPF1
SecondaryPart A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm

Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.

Time frame:
Baseline (Day -1) and at Day 38
Reported as:
Count of participants · Participants
Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm
ParticipantsPart A: OCA 10 mg + Linerixibat 90 mg
Cellular casts: No change1
Cellular casts: Increase to 1-9/HPF0
Erythrocytes: No change0
Erythrocytes: Increase to 1-9/HPF1
Granular casts: No change1
Granular casts: Increase to 1-9/HPF0
Hyaline casts: No change1
Hyaline casts: Increase to 1-9/HPF0
Leukocytes: No change1
Leukocytes: Increase to 1-9/HPF0
SecondaryPart B- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.

Time frame:
Baseline (Day -1), and up to Day 38

No measurements were reported for this outcome.

SecondaryPart A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Geometric mean · Hours*picogram per milliliter
Part A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm
Hours*picogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Day 20, n=16230.609 ± 153.14
Day 33, n=19903.881 ± 142.27
SecondaryPart A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Geometric mean · Hours*picogram per milliliter
Part A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm
Hours*picogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Day 20, n=13322.580 ± 121.05
Day 33, n=171071.982 ± 144.57
SecondaryPart A- Cmax for Linerixibat: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Geometric mean · Picogram per milliliter
Part A- Cmax for Linerixibat: OCA + Linerixibat Arm
Picogram per milliliterPart A: OCA 10 mg + Linerixibat 90 mg
Day 20, n=1756.927 ± 173.55
Day 33, n=19163.624 ± 123.48
SecondaryPart A- Tmax for Linerixibat: OCA + Linerixibat Arm

Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Reported as:
Median · Hours
Part A- Tmax for Linerixibat: OCA + Linerixibat Arm
HoursPart A: OCA 10 mg + Linerixibat 90 mg
Day 20, n=173.92 (0.3 to 8.0)
Day 33, n=195.00 (0.5 to 9.0)
SecondaryPart B- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryPart B- AUC(0-12) for Linerixibat: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryPart B- Cmax for Linerixibat: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryPart B- Tmax for Linerixibat: OCA + Linerixibat Arm

Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.

Time frame:
Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose

No measurements were reported for this outcome.

Adverse events

Collected over AEs and SAEs were collected up to Day 52 in Part A. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: OCA 10 mg0/19 (0%)0/19 (0%)10/19 (52.6%)
Part A: OCA 10 mg + Linerixibat 90 mg0/19 (0%)1/19 (5.3%)14/19 (73.7%)
Most frequent serious events
Most frequent serious events
EventPart A: OCA 10 mgPart A: OCA 10 mg + Linerixibat 90 mg
Deep vein thrombosisVascular disorders0/191/19
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPart A: OCA 10 mgPart A: OCA 10 mg + Linerixibat 90 mg
Abdominal discomfortGastrointestinal disorders0/195/19
DiarrhoeaGastrointestinal disorders0/194/19
HeadacheNervous system disorders4/191/19
NasopharyngitisInfections and infestations3/190/19
Dermatitis contactSkin and subcutaneous tissue disorders2/191/19
RashSkin and subcutaneous tissue disorders1/192/19
Transaminases increasedInvestigations0/192/19
Decreased appetiteMetabolism and nutrition disorders1/192/19
Abdominal painGastrointestinal disorders1/191/19
Abdominal pain upperGastrointestinal disorders1/190/19

Baseline characteristics

The study was concluded after complete analysis of Part A, there was no clinical benefit seen in conducting Part B of this study, no participants were enrolled in Part B.

Age, Continuous
Age, Continuous(Years)Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mgTotal
Mean44.9 ± 10.28—44.9 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mgTotal
Female1—1
Male18—18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mgPart B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mgTotal
Black or African American1—1
White - White/Caucasian/European Heritage18—18
08

Study locations

1 site
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a data sharing agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Nov 2019, 2 months.

Results were first posted in Jul 2020, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 12, 2019
StartActual
Aug 27, 2019
Primary completionActual
Nov 25, 2019
CompletionActual
Nov 25, 2019
Results first posted
Jul 24, 2020
Last update
Jul 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04053023
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 12, 2019
Start date
Aug 27, 2019
Primary completion
Nov 25, 2019
Completion
Nov 25, 2019
Results posted
Jul 24, 2020
Last update
Jul 24, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linerixibat · Obeticholic acid

Start the discussion